Logo

Novartis's Capmatinib (INC280) Receives the US FDA's Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer

Share this

Novartis's Capmatinib (INC280) Receives the US FDA's Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer

Shots:

  • The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology
  • The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints
  • Capmatinib (INC280) is an oral potent and selective MET inhibitor with expected regulatory submission in Q4’19. In 2009- Novartis signed an exclusive development and commercialization agreement with Incyte for Capmatinib

Click here to­ read full press release/ article 

Ref: Novartis | Image: Novartis 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions